Central Nervous System Toxoplasmosis in Relapsed Hodgkin’s Lymphoma: A Case Report

Hassan Abolghasemi,1 Ehsan Shahverdi,2,* Ramezan Jafari,3 Fardin Dolatimehr,4 and Azam Khandani5

1Department of Pediatrics, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2Blood Transfusion Research Center/High Institute for Research Center & Education in Transfusion Medicine, Immunohematology Department, Tehran, IR Iran
3Department of Radiology, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4Students’ Research Committee (SRC), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
5Islamic Azad University of Nursing Sciences, Najafabad, Esfahan, IR Iran

*Corresponding author: Ehsan Shahverdi, Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-2188620826, E-mail: shahverdi_ehsan@yahoo.com

Received 2016 February 27; Revised 2016 April 10; Accepted 2016 June 05.

Abstract

Introduction: Patients with immunosuppression have an increased incidence of toxoplasmosis characterized by involvement of the central nervous system. Only a few cases of toxoplasmosis associated with immunosuppressive agents have been reported. Such cases have been reported in immune suppressed patients outside the Iran, but a search of the literature has not revealed any previous reports from this country.

Case Presentation: We described a 17-year-old male, a known case of Hodgkin’s lymphoma with the diagnosis of central nervous system (CNS) toxoplasmosis.

Conclusions: As a conclusion, CNS toxoplasmosis should be considered in the differential diagnosis of immunosuppressed patients who present with neurological manifestations.

Keywords: Toxoplasmosis, Central Nervous System, Hodgkin’s Disease

1. Introduction

Patients with malignancies who have received chemotherapy have an increased incidence of severe and diffused toxoplasmosis with involvement of the central nervous system (CNS) (1).

Patients with Hodgkin’s disease seem to be individually threatened (2) because of immunological Immunodeficiency associated with the underlying disease and the treatment modalities or both. In previous reported, toxoplasmosis have occurred after the initiation of antineoplastic therapy (3-6). The difficulty in clinical diagnosis of cerebral toxoplasmosis is related to the lack of pathognomonic clinical or radiological features (7). We describe CNS toxoplasmosis in the patient with relapsed/treated Hodgkin’s disease.

1.1. Implication

CNS toxoplasmosis should be considered in the differential diagnosis of immunosuppressed patients who present with neurological manifestations.

1.2. Ethical Considerations

This study was approved in ethics committee of Baqiyatallah University of Medical Sciences. Patient was asked to sign an informed consent form for publication. All the terms of Helsinki declaration were considered and the personal information remained anonymous.

2. Case Presentation

A 17-year-old male, a known case of Hodgkin’s lymphoma was admitted to our hospital with anorexia, diplopia, lethargy, and right leg claudication from 3 days before admission. Hodgkin’s lymphoma was in remission phase for about 7 years. Six months before admission, he was admitted to hospital because of fever, night sweats, fatigue, weight loss, splenomegaly, and multiple cervical, retroperitoneal and para-aortic lymphadenopathy that brought up a presumptive diagnosis of relapsed phase of Hodgkin’s disease. The patient was evaluated for staging and treatment. Pathological staging and biopsy of cervical lymph nodes showed stage IIIIB of Hodgkin’s lymphoma recurrence. He received chemotherapy for 4 months.
On the tenth day of hospitalization, the temperature briefly rose to 39°C, and photophobia, nuchal, passive and active foot rigidity developed.

On a neurological examination, outward deviation, mydriasis, ptosis and lack of response to light were observed in the right eye. Other cranial nerves were intact. His motor strength was 5/5 in the left extremities and 4/5 in the right extremities with normal sensation. He showed dysmetria and mild hyperreflexia on the right side. Tremor in the right extremities with normal sensation. He showed speech was dramatically improved but motor sequelae remained.

MRI of the brain at 6 weeks after anti-toxoplasmosis therapy initiation, progression of disease was stopped, his}

3. Discussion

Diffuse toxoplasmosis with CNS involvement is a life-threatening disease which often avoids diagnosis (1, 8). In a review of 45 patients with CNS-toxoplasmosis, less than 40% were diagnosed prior to death. However, early diagnosis of the disease has been rewarded by a rapid response to treatment (8).

Clinical reactivation is often associated with patient immunosuppression (9). Our patient was immunosuppressed because of Hodgkin’s disease and chemotherapy. The common presentation in immunosuppressed patients includes: meningoencephalitis, pneumonitis and infection (9). Focal neurological deficits are also common in immunocompromised patients (10). Some studies reported psychiatric disorders in these patients (7). Neurological deficits were of the first features of cerebral toxoplasmosis in our patient and he was also depressed and had phobia and anxiety disorders.

In a review of 85 AIDS patients with cerebral toxoplasmosis, ten (8.5%) patients did not present with any focal neurological signs. Also, the oculomotor nerve (66%) was the most frequently involved cranial nerve. In the recent case, all cranial nerves were intact.

According to centers for disease control and prevention (CDC) guidelines, criteria for establishing the diagnosis of cerebral toxoplasmosis includes the proper clinical features, consistent findings on imaging, positive serological studies, and a therapeutic response to treatment (11). All these four criteria were existed in our patient.

Only a few cases of toxoplasmosis associated with immunosuppressive agents have been reported (12-14).

The laboratory diagnosis of acute toxoplasmosis depends on serological technique (1). The most common
serologic criteria are an elevated concentration of IgM Toxoplasma antibody and rise in IgG titer. In our patient, both IgM and IgG levels were increased.

CT images usually show hypodense lesions with ring enhancement or nodular enhancing lesions (15). MRI findings in CNS lymphoma included: subependymal spread and homogenous enhancement. CNS toxoplasma lesions are usually located within grey matter - white matter junction and basal ganglia and showed ring like or nodular enhancement. Also, hemorrhagic changes (TIW hyperintensity) is more likely happened in Toxoplasma rather than lymphoma.

The most frequent therapy for cerebral toxoplasmosis is pyrimethamine and sulfadiazine along with folic acid to reduce hematological complications of pyrimethamine (15). As we used for our patient. Clindamycin is used for patients allergic to sulfa drugs (15) but it should be used in combination with pyrimethamine. The potential use of clindamycin as a single agent has not been established in randomized clinical trials (16). Roemer et al. (17) used clindamycin to treat a patient with cerebral toxoplasmosis but the patient died. While Yapar et al. (18) used clindamycin alone to treat cerebral toxoplasmosis but it took more times for complete radiological clearance of the lesions. Our patient showed good clinical improvement within 4 days and the lesion resolved approximately within 3 weeks.

A positive response to treatment can be demonstrated both clinically and radiologically. Patil et al. (19) repeated CT scan after 21 days of treatment to demonstrate response to anti-Toxoplasma therapy.

Figure 1. MRI of the Brain

A and B, axial T2W and FLAIR; C, Gadolinium enhanced MRI study.

Figure 2. MRI Following Anti-Toxoplasma Therapy

D, Axial T2; E, FLAIR; F, post-contrast.

Acknowledgments
None declared.

Footnotes

Authors’ Contributions: All authors contributed equally in this project.

Conflict of Interest: There is no conflict of interest.

Financial Disclosure: None declared.

Funding/Support: None declared.

References

1. Ruskin J, Remington JS. Toxoplasmosis in the compromised host. Ann Intern Med. 1976; 84(2):193–9. [PubMed: 766684].
2. Vietzke WM, Gelderman AH, Grimeley PM, Valsamis MP. Toxoplasmosis complicating malignancy. Experience at the National Cancer Institute. Cancer. 1968; 21(5):816–27. [PubMed: 4296934].
3. Gleason TH, Hamlin WB. Disseminated toxoplasmosis in the compromised host. A report of five cases. Arch Intern Med. 1974; 134(6):1059–62. [PubMed: 4215377].
4. Masson R, Fiere D, Lahneche B, Cordat C, Berger F, Revol L. [Encephalic pseudotumoral toxoplasmosis in the course of blood diseases]. Nouv Presse Med. 1975; 4(35):2499–502. [PubMed: 1155022].
5. Sarbach B. [Cerebral complications (viral encephalopathy, toxoplasmosis) in two patients with treated Hodgkin’s disease. Clinical and pathological study (author’s transl)]. Acta Neurol Belg. 1975; 75(2):65–84. [PubMed: 1155022].
6. Vallat M, Pesme D, Durand M, Hoerni B. [Acquired toxoplasmosis during the course of Hodgkin’s disease]. Nouv Presse Med. 1976; 3(38):2534–3. [PubMed: 980786].
7. Anderson SE, Remington JS. The diagnosis of toxoplasmosis. South Med J. 1975; 64(1):343–41. [PubMed: 1803308].
8. Townsend JF, Wolinsky JS, Baringer JR, Johnson PC. Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol. 1975; 32(5):335–43. [PubMed: 1094993].
9. Halonen SK, Chiu F, Weiss LM. Effect of cytokines on growth of Toxoplasma gondii in murine astrocytes. Infect Immun. 1998; 66(10):4989–93. [PubMed: 9746608].
10. Silva LA, Vieira RS, Serafim LN, Carlotti CG Jr, Figueiredo JF. [Toxoplasmosis of the central nervous system in a patient without immunosuppression: case report]. Rev Soc Bras Med Trop. 2001; 34(5):467–90. [PubMed: 1600997].
11. Control CfD prevention centers for disease control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *Morb Mortal Wkly Rep.* 1993;41:1-10.

12. Pulivarthi S, Reshi RA, McGary CT, Gurram MK. Cerebral toxoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis. *Intern Med.* 2015;54(11):1433-6. doi: 10.2169/internalmedicine.54.3977. [PubMed: 26022002].

13. Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. *JAMA Intern Med.* 2013;173(10):924-6. doi: 10.1001/jamainternmed.2013.374. [PubMed: 23589123].

14. Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. *N Engl J Med.* 2005;353(14):1530-1. doi: 10.1056/NEJMoa051556. [PubMed: 16207863] discussion 1530-1.

15. Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. *Future Microbiol.* 2009;4(10):1363-79. doi: 10.2217/fmb.09.89. [PubMed: 19995194].

16. Madi D, Achappa B, Rao S, Ramapuram JT, Mahalingam S. Successful treatment of cerebral toxoplasmosis with clindamycin: a case report. *Oman Med J.* 2012;27(5):411-2. doi: 10.5001/omj.2012.100. [PubMed: 23074553].

17. Roemer E, Blau IW, Basara N, Kiehl MG, Bischoff M, Gunzelmann S, et al. Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-center experience. *Clin Infect Dis.* 2001;32(1):51-8. doi: 10.1086/317548. [PubMed: 11383978].

18. Yapar N, Erdenizmenli M, Oguz VA, Cakir N, Yuce A. Cerebral toxoplasmosis treated with clindamycin alone in an HIV-positive patient allergic to sulfonamides. *Int J Infect Dis.* 2005;9(1):64-6. doi: 10.1016/j.ijid.2004.05.004. [PubMed: 15603998].

19. Patil HV, Patil VC, Rajmane V, Raje V. Successful treatment of cerebral toxoplasmosis with cotrimoxazole. *Indian J Sex Transm Dis.* 2011;32(4):34-6. doi: 10.4103/0253-7384.81255. [PubMed: 21799577].